abstract: BACKGROUND: Many factors are associated with @entity4 ( @entity4 ) phenomenon in @entity2 ( @entity2 ), including plasma @entity1 , age, and pre-percutaneous coronary intervention (PCI) @entity3 score. Initial clinical assessment would benefit from accurate @entity4 prediction. This study aimed to develop a simple scoring system to predict the risk of @entity4 in @entity0 undergoing primary PCI with @entity2 . METHODS: Baseline clinical and procedural variables were used for risk score development (the training dataset, n   =   912) and validation (the test dataset, n   =   864). Independent predictors of @entity4 from the multivariable model were assigned integer weights based on their coefficients and incorporated into a risk score. The discriminant ability of the score was tested by receiver operating characteristic analysis using the test dataset. RESULTS: The final model included 7 significant variables, which were age, pain-to-PCI time, neutrophil count, admission plasma @entity1 level, pre-PCI @entity3 score, collateral circulation, and Killip class. All these variables were then used to build a risk score in terms of the prediction of @entity4 . Receiver operating characteristic analysis demonstrated good risk prediction with a c statistic of 0.800 (95% confidence interval: 0.772-0.826) in the test dataset. CONCLUSIONS: In @entity0 with @entity2 treated by primary PCI, incidence of @entity4 phenomenon may be predicted with an acceptable accuracy based on a 7-item simplified risk score.

title: A Risk Score for No Reflow in @entity0 With ST-Segment Elevation XXXX After Primary Percutaneous Coronary Intervention.

answer: @entity2


abstract: BACKGROUND: Many factors are associated with @entity4 ( @entity4 ) phenomenon in @entity2 ( @entity2 ), including plasma @entity1 , age, and pre-percutaneous coronary intervention (PCI) @entity3 score. Initial clinical assessment would benefit from accurate @entity4 prediction. This study aimed to develop a simple scoring system to predict the risk of @entity4 in @entity0 undergoing primary PCI with @entity2 . METHODS: Baseline clinical and procedural variables were used for risk score development (the training dataset, n   =   912) and validation (the test dataset, n   =   864). Independent predictors of @entity4 from the multivariable model were assigned integer weights based on their coefficients and incorporated into a risk score. The discriminant ability of the score was tested by receiver operating characteristic analysis using the test dataset. RESULTS: The final model included 7 significant variables, which were age, pain-to-PCI time, neutrophil count, admission plasma @entity1 level, pre-PCI @entity3 score, collateral circulation, and Killip class. All these variables were then used to build a risk score in terms of the prediction of @entity4 . Receiver operating characteristic analysis demonstrated good risk prediction with a c statistic of 0.800 (95% confidence interval: 0.772-0.826) in the test dataset. CONCLUSIONS: In @entity0 with @entity2 treated by primary PCI, incidence of @entity4 phenomenon may be predicted with an acceptable accuracy based on a 7-item simplified risk score.

title: A Risk Score for No Reflow in XXXX With ST-Segment Elevation @entity2 After Primary Percutaneous Coronary Intervention.

answer: @entity0


abstract: BACKGROUND: The Walgreens Connected Care @entity1 (CCMS) treatment management program provides enhanced levels of monitoring, oversight, and care for @entity0 taking MS disease-modifying agents. This study compared rates of adherence to MS medications for @entity0 participating in the CCMS program for at least 6 months with those for @entity0 participating for less than 6 months. For a subsample of @entity0 , we also examined the relationship between adherence and the presence of @entity3 or @entity2 . METHODS: This was a retrospective study of @entity0 new to the CCMS program and followed up for 1 year of participation. Adherence to MS medications was measured as the proportion of days covered, with propensity scores used to match the CCMS intervention group to the less-managed comparison group. The impact of program participation on the relationship between @entity2 or @entity3 and adherence over time was a separate analysis. RESULTS: Mean proportion of days covered rates improved significantly in the group managed for at least 6 months compared with those who were less managed. Positive screenings for @entity3 and @entity2 reduced adherence in the less-managed group but not in @entity0 with longer participation in the program. CONCLUSIONS: Overall, the CCMS program significantly increased adherence to MS medications. This improved adherence was not negatively impacted by positive screenings for @entity3 and @entity2 .

title: Walgreens connected care: impact of managed therapy on adherence to medications used to treat XXXX and related comorbid conditions.

answer: @entity1


abstract: @entity2 and @entity3 constitute 42% to 45% of the @entity1 in @entity0 , @entity0 , and adolescents: In 1985, an estimated 2025 @entity0 were newly diagnosed with these two @entity1 and 900 (43%) of the @entity1 deaths in the United States have been projected to be due to these diseases. The single most important obstacle to preventing these deaths is relapse, and prevention of relapse or salvage of the @entity0 who has had a relapse continues to be a major therapeutic challenge. The most important initial step in the treatment of the @entity0 whose disease has relapsed is to determine, to the extent possible, the prognosis. In a @entity0 with @entity3 , a relapse confers an extremely poor prognosis, regardless of site of relapse, @entity1 histology, or other original prognostic factors, prior therapy, or time to relapse. In the @entity0 with @entity2 in relapse, the prognosis depends on multiple factors. The primary therapy is chemotherapy or chemoradiotherapy with marrow grafting. Other options exist, including no therapy, or investigational therapy. The therapy selected should be predicated on the prognosis. In the @entity0 with an isolated central nervous system (CNS) relapse off therapy, minimum therapy should be administered, particularly if the relapse occurred without prior cranial irradiation. In the @entity0 whose relapse is more than 6 months off therapy, conventional therapy should be considered. Also, a @entity0 with an isolated CNS relapse on therapy after prior cranial irradiation should be given moderate therapy. Bone marrow transplantation or high-dose chemoradiotherapy with autologous marrow rescue should be reserved in @entity0 with a second or subsequent extramedullary relapse, and possibly for those with a first isolated overt testicular relapse on therapy.

title: Prognosis and treatment after relapse of XXXX and @entity3 : 1985. A report from the Childrens Cancer Study Group.

answer: @entity2


abstract: @entity2 and @entity3 constitute 42% to 45% of the @entity1 in @entity0 , @entity0 , and adolescents: In 1985, an estimated 2025 @entity0 were newly diagnosed with these two @entity1 and 900 (43%) of the @entity1 deaths in the United States have been projected to be due to these diseases. The single most important obstacle to preventing these deaths is relapse, and prevention of relapse or salvage of the @entity0 who has had a relapse continues to be a major therapeutic challenge. The most important initial step in the treatment of the @entity0 whose disease has relapsed is to determine, to the extent possible, the prognosis. In a @entity0 with @entity3 , a relapse confers an extremely poor prognosis, regardless of site of relapse, @entity1 histology, or other original prognostic factors, prior therapy, or time to relapse. In the @entity0 with @entity2 in relapse, the prognosis depends on multiple factors. The primary therapy is chemotherapy or chemoradiotherapy with marrow grafting. Other options exist, including no therapy, or investigational therapy. The therapy selected should be predicated on the prognosis. In the @entity0 with an isolated central nervous system (CNS) relapse off therapy, minimum therapy should be administered, particularly if the relapse occurred without prior cranial irradiation. In the @entity0 whose relapse is more than 6 months off therapy, conventional therapy should be considered. Also, a @entity0 with an isolated CNS relapse on therapy after prior cranial irradiation should be given moderate therapy. Bone marrow transplantation or high-dose chemoradiotherapy with autologous marrow rescue should be reserved in @entity0 with a second or subsequent extramedullary relapse, and possibly for those with a first isolated overt testicular relapse on therapy.

title: Prognosis and treatment after relapse of @entity2 and XXXX : 1985. A report from the Childrens Cancer Study Group.

answer: @entity3


abstract: UNASSIGNED: Controllable induction of blood vessel formation (angiogenesis) presents an important therapeutic goal in @entity2 and is also beneficial in various normal physiological processes. In this study, we have shown that nanoparticles of @entity7 , a lipophilic nonsteroidal anti-inflammatory drug, effectively evoke therapeutic angiogenesis in animal models, in both normal and @entity2 organs. @entity7 is widely considered to inhibit angiogenesis, although a recent study suggests that it can instead promote blood vessel growth in @entity0 cell lines. The hydrophobic nature of this drug necessitates its administration in nanoparticulate form in order to elicit a perceivable pharmacological response. We developed a facile method for nanoparticle formation by solvent extraction from microemulsions in supercritical @entity3 . This method exploits a spontaneous formation of nanometric domains within the microemulsion system and their rapid conversion to nanoparticles by supercritical fluid. The resultant nanoparticles were administered subcutaneously to @entity1 in a biocompatible hydrogel, and caused a 4-fold increase in blood vessel count in normally perfused skin compared with drug-free particles. They were at least as effective in inducing angiogenesis as nanoparticles of @entity6 , a well-established neovascularization promoter. Next, we evaluated their effect on @entity2 tissues in @entity1 model of @entity4 . We found that @entity7 nanoparticles were able to induce a significant vascularization of @entity2 myocardium and hamper the progression of @entity5 , which points toward a new approach for treating @entity2 .

title: XXXX Nanoparticles for Therapeutic Angiogenesis.

answer: @entity7


abstract: BACKGROUND: The role of a mixture of phlebotonics in the treatment of acute @entity8 crisis is investigated to test their efficacy. METHODS: One hundred and thirty-four consecutive @entity0 with an acute @entity8 recruited in five colorectal units entered the study. Sixty-six of them were randomized to receive a mixture of @entity9 , @entity10 and @entity11 (group A), and 68 a placebo (group B). The main symptoms, the use of @entity6 and the Bristol scale score were recorded at each scheduled visit and compared using both Student's t test for independent samples and the ANOVA models for repeated measures. The presence of @entity1 , prolapse and @entity4 were also recorded and compared using the Chi-square test. Furthermore, the trend of proportions during the time of the evaluations was assessed by the Chi-square test for linear trend. RESULTS: @entity2 , @entity3 and the proportion of @entity0 who reported persistence of @entity1 and @entity4 decreased significantly after 12  days of treatment in group A. After 6  days, the number of @entity5 tablets taken by @entity0 in group A was significantly lower than the amount of @entity7 mixture. CONCLUSIONS: The use of a mixture of @entity9 , @entity10 and @entity11 is a safe and effective mean of managing symptoms of acute @entity8 . Furthermore, in @entity0 receiving treatment, there was faster control and lower persistence of @entity1 and @entity4 .

title: Flavonoids mixture ( @entity9 , XXXX , @entity11 ) in the treatment of acute @entity8 : a prospective, randomized, triple-blind, controlled trial.

answer: @entity10


abstract: BACKGROUND: The role of a mixture of phlebotonics in the treatment of acute @entity8 crisis is investigated to test their efficacy. METHODS: One hundred and thirty-four consecutive @entity0 with an acute @entity8 recruited in five colorectal units entered the study. Sixty-six of them were randomized to receive a mixture of @entity9 , @entity10 and @entity11 (group A), and 68 a placebo (group B). The main symptoms, the use of @entity6 and the Bristol scale score were recorded at each scheduled visit and compared using both Student's t test for independent samples and the ANOVA models for repeated measures. The presence of @entity1 , prolapse and @entity4 were also recorded and compared using the Chi-square test. Furthermore, the trend of proportions during the time of the evaluations was assessed by the Chi-square test for linear trend. RESULTS: @entity2 , @entity3 and the proportion of @entity0 who reported persistence of @entity1 and @entity4 decreased significantly after 12  days of treatment in group A. After 6  days, the number of @entity5 tablets taken by @entity0 in group A was significantly lower than the amount of @entity7 mixture. CONCLUSIONS: The use of a mixture of @entity9 , @entity10 and @entity11 is a safe and effective mean of managing symptoms of acute @entity8 . Furthermore, in @entity0 receiving treatment, there was faster control and lower persistence of @entity1 and @entity4 .

title: Flavonoids mixture ( XXXX , @entity10 , @entity11 ) in the treatment of acute @entity8 : a prospective, randomized, triple-blind, controlled trial.

answer: @entity9


abstract: BACKGROUND: The role of a mixture of phlebotonics in the treatment of acute @entity8 crisis is investigated to test their efficacy. METHODS: One hundred and thirty-four consecutive @entity0 with an acute @entity8 recruited in five colorectal units entered the study. Sixty-six of them were randomized to receive a mixture of @entity9 , @entity10 and @entity11 (group A), and 68 a placebo (group B). The main symptoms, the use of @entity6 and the Bristol scale score were recorded at each scheduled visit and compared using both Student's t test for independent samples and the ANOVA models for repeated measures. The presence of @entity1 , prolapse and @entity4 were also recorded and compared using the Chi-square test. Furthermore, the trend of proportions during the time of the evaluations was assessed by the Chi-square test for linear trend. RESULTS: @entity2 , @entity3 and the proportion of @entity0 who reported persistence of @entity1 and @entity4 decreased significantly after 12  days of treatment in group A. After 6  days, the number of @entity5 tablets taken by @entity0 in group A was significantly lower than the amount of @entity7 mixture. CONCLUSIONS: The use of a mixture of @entity9 , @entity10 and @entity11 is a safe and effective mean of managing symptoms of acute @entity8 . Furthermore, in @entity0 receiving treatment, there was faster control and lower persistence of @entity1 and @entity4 .

title: Flavonoids mixture ( @entity9 , @entity10 , XXXX ) in the treatment of acute @entity8 : a prospective, randomized, triple-blind, controlled trial.

answer: @entity11


abstract: BACKGROUND: The role of a mixture of phlebotonics in the treatment of acute @entity8 crisis is investigated to test their efficacy. METHODS: One hundred and thirty-four consecutive @entity0 with an acute @entity8 recruited in five colorectal units entered the study. Sixty-six of them were randomized to receive a mixture of @entity9 , @entity10 and @entity11 (group A), and 68 a placebo (group B). The main symptoms, the use of @entity6 and the Bristol scale score were recorded at each scheduled visit and compared using both Student's t test for independent samples and the ANOVA models for repeated measures. The presence of @entity1 , prolapse and @entity4 were also recorded and compared using the Chi-square test. Furthermore, the trend of proportions during the time of the evaluations was assessed by the Chi-square test for linear trend. RESULTS: @entity2 , @entity3 and the proportion of @entity0 who reported persistence of @entity1 and @entity4 decreased significantly after 12  days of treatment in group A. After 6  days, the number of @entity5 tablets taken by @entity0 in group A was significantly lower than the amount of @entity7 mixture. CONCLUSIONS: The use of a mixture of @entity9 , @entity10 and @entity11 is a safe and effective mean of managing symptoms of acute @entity8 . Furthermore, in @entity0 receiving treatment, there was faster control and lower persistence of @entity1 and @entity4 .

title: Flavonoids mixture ( @entity9 , @entity10 , @entity11 ) in the treatment of acute XXXX : a prospective, randomized, triple-blind, controlled trial.

answer: @entity8


abstract: INTRODUCTION: The aim of this study was to evaluate the clinical and radiological outcome of the Total Evolutive Shoulder System (TESS) in @entity0 with cuff tear @entity2 and @entity0 in need of a revision arthroplasty. METHODS: In this sequential study, 67 @entity0 (56 non-stemmed, 11 stemmed) were evaluated after a mean follow-up of 17.5  months. The relative Constant and DASH scores, radiological joint geometry changes, complications and @entity1 , which are not likely to affect the outcome, were evaluated. RESULTS: A significant increase was noticed for the relative Constant (11.3 vs. 78.8  %) and DASH scores (73.7 vs. 31.8) without significant differences between both etiology groups. Complication rates were similar to previous studies. An aseptic loosening of the non-stemmed humeral component was not noticed in the cuff tear @entity2 group, whereas one case with a loosening was noticed in the revision arthroplasty group. With nine cases (13.4  %), scapular notching rates were very low. On average, the acromiohumeral distance increased by 17  mm and the humeral offset by 13.9  mm; the height of the center of rotation decreased by 4.6  mm and the lateral glenohumeral offset by 6.1  mm, p  <  0.05, respectively. CONCLUSION: Regarding the joint geometry, surgery with the TESS system provided adequate distalization and medialization of the humerus and the center of rotation. This corresponds to a good clinical outcome. The use of the surgical opportunity to implant the prosthesis with a relatively low neck-shaft angle might explain the low rates of scapular notching in our series. Regarding the case with a loosening of the humeral component, the surgeon should carefully indicate a stemless version for metaphyseal press-fit fixation in @entity0 with revision arthroplasty.

title: Short-term results of the reverse Total Evolutive Shoulder System (TESS) in cuff tear XXXX and revision arthroplasty cases.

answer: @entity2


abstract: INTRODUCTION: The PROROK project (A prospective observation project to assess the relevance of the difference between fasting glycemia and postprandial glycemia to estimation of success of type 2 @entity1 therapy) had a character of a non-interventional, prospective, multicentric observation project conducted for a period of 6 months, whose aim was to quantify the relevance of the difference between fasting and postprandial glycemia to the success of @entity4 agonist treatment, or insulin therapy with basal or premixed insulin, or a combination of basal and bolus insulin. Physicians chose therapy for inadequately compensated @entity0 at their own discretion, with 4   972 @entity0 included. AIM: The study aimed at the assessment of the differences in basic anthropometric and biochemical parameters between the @entity0 cohorts included in the PROROK project with regard to the therapy selected by the treating diabetologist. METHODOLOGY AND RESULTS: The @entity0 treated with @entity4 agonists were quite young, they have suffered from @entity1 for a shorter period of time and at the same time were more @entity2 and had the highest concentration of @entity3 . The @entity0 who underwent basal insulin therapy, had the highest fasting glycemia. The @entity0 for whom premixed insulin therapy or basal/bolus insulin regimen were chosen, manifested the highest postprandial glycemia, those with basal/bolus insulin regimen had the highest initial glycated haemoglobin. The difference between fasting and postprandial glycemia was the smallest in the cohort for which basal insulin therapy was chosen and the greatest in the cohort chosen for the therapy with premixed insulin, or with the basal/bolus insulin combination. Average improvement in glycated haemoglobin values reached 1.6 % within the whole cohort, a median of the resulting glycated haemoglobin reached 5.9 % or 5.8 % ( @entity4 agonist treatment). All the differences amounted to p < 0.001. CONCLUSION: Bearing in mind that the differences established in the parameters describing the cohorts, although statistically relevant, are of smaller clinical relevance, we regard as an important finding that the choice of therapy is in accordance with the basic knowledge about the pathophysiology of type 2 @entity1 and possibilities of an individually chosen targeted intervention with antidiabetic therapy. We may conclude that most of the physicians participating in the PROROK project choose their therapy in a rational manner.Key words: @entity4 agonists - basal insulin - intensified insulin regimen - insulin - premixed insulin - type 2 @entity1 therapy.

title: [Do diabetologists choose a  therapy rationally? Basic results of the PROROK project (A prospective observation project to assess the relevance of the difference between fasting glycemia and postprandial glycemia to estimation of success of type 2  XXXX therapy)].

answer: @entity1


abstract: OBJECTIVE: To identify factors that impact the procedure and treatment outcomes for endoscopic full-thickness resection (EFTR) of @entity3 ( @entity1 ). METHODS: Medical records were collected for all @entity0 with gastric @entity1 who underwent EFTR procedures in Shengjing Hospital between June 2012 and April 2014. The data from each @entity0 were reviewed, including gender, age, maximum @entity1 size on endoscopic ultrasound (EUS), @entity1 location in stomach, length of EFTR procedure, @entity4 during EFTR, cost to close defects, length of hospital stay after the procedure, and procedure-related complications. RESULTS: Endoscopic full-thickness resection of gastric @entity1 was successfully performed in all 41 @entity0 . Maximum size on EUS [parameter estimate (PE)  =  4.443, 95  % confidence interval (CI) 2.191-6.695; p  =  0.000] and @entity1 location in the greater curvature (PE  =  44.441, 95  % CI 5.539-83.343; p  =  0.026) were significantly associated with the length of the procedure. @entity4 was more likely to occur during EFTR in @entity1 with a larger EUS size [odds ratio (OR)  =  1.415, 95  % CI 1.034-1.936; p  =  0.03], and less likely to occur during EFTR for @entity1 located in the posterior wall (OR  =  0.003, 95  % CI 0-0.351; p  =  0.017). The use of the over-the-scope clip (OTSC) system was significantly associated with shorter hospital stays (PE  =  -1.006, 95  % CI -1.998 to -0.014; p  =  0.047) and a higher cost of @entity2 (PE  =  854.742, 95  % CI 358.377-1351.107; p  =  0.001). CONCLUSIONS: Endoscopic full-thickness resection is an effective and safe method for removing gastric @entity1 . @entity1 size on EUS and location of the @entity1 were associated with the duration of EFTR and the occurrence of a @entity4 during the procedure. The use of an OTSC system was significantly associated with shorter hospital stays and a higher cost of @entity2 .

title: Factors associated with endoscopic full-thickness resection of XXXX .

answer: @entity3


abstract: BACKGROUND: @entity3 is characteristic of @entity4 and also occurs with normal aging. Our goal was to determine the upper limit of normal for number of @entity5 . METHODS: Core-needle biopsies of the renal cortex were obtained at the time of living kidney transplantation at three centers between 1998 and 2011. The number of @entity5 was averaged across two biopsy sections. Quantile regression was used to estimate the 95th percentile for @entity5 as the upper reference limit. There were 2052 donors (mean age 43 years, 41% male, 10% @entity1 ), with a mean (SD) of 16.0 (9.7) glomeruli and 0.47 (0.99) @entity5 on biopsy; only 2.6% had >5% @entity0 . RESULTS: In a multivariable model excluding @entity1 donors, independent predictors of the number of @entity5 were age, total number of @entity2 . A simplified model was used to estimate the 95th percentile for number of @entity5 by total number of glomeruli and age. For a biopsy section with 17-32 total glomeruli, the 95th percentile ranged from 1 for a 20-year old to 5.5 for a 70-year old donor. @entity1 donors were more likely to have an abnormal number of @entity5 (OR = 1.79, P = 0.035). CONCLUSIONS: We have derived the 95% reference limit for number of @entity5 in ostensibly healthy individuals accounting for age and the biopsy characteristics. Numbers of @entity5 in a kidney biopsy that exceed these thresholds suggest chronic pathological injury in excess of that expected with normal aging.

title: Distinguishing age-related from disease-related XXXX on kidney biopsy: the Aging Kidney Anatomy study.

answer: @entity3


abstract: Bioconvection is a form of collective motion that occurs spontaneously in the suspension of swimming microorganisms. In a previous study, we quantitatively described the "pattern transition," a phase transition phenomenon that so far has exclusively been observed in bioconvection of the unicellular green alga @entity0 . We suggested that the transition could be induced by changes in the balance between the gravitational and shear-induced torques, both of which act to determine the orientation of the organism in the shear flow. As both of the torques should be affected by the geometry of the @entity0 cell, alteration in the flagellar waveform might change the extent of torque generation by altering overall geometry of the cell. Based on this working hypothesis, we examined bioconvection behavior of two flagellar mutants of @entity0 , ida1 and @entity1 , making reference to the wild type. Flagella of ida1 beat with an abnormal waveform, while flagella of @entity1 show a normal waveform but lower beat frequency. As a result, both mutants had swimming speed of less than 50% of the wild type. ida1 formed bioconvection patterns with smaller spacing than those of wild type and @entity1 . Two-axis view revealed the periodic movement of the settling blobs of ida1, while @entity1 showed qualitatively similar behavior to that of wild type. Unexpectedly, ida1 showed stronger negative gravitaxis than did wild type, while @entity1 showed relatively weak gravitaxis. These findings suggest that flagellar waveform, not swimming speed or beat frequency, strongly affect bioconvection behavior in @entity0 .

title: Individual Flagellar Waveform Affects Collective Behavior of XXXX .

answer: @entity0


abstract: INTRODUCTION: Renal function is reported using the estimates of glomerular filtration rate (eGFR). However, eGFR values are recorded without reference to the particular serum @entity3 (SCr) assays used to derive them, and newer assays were introduced at different time points across the laboratories in the United Kingdom. These changes may cause systematic bias in eGFR reported in routinely collected data, even though laboratory-reported eGFR values have a correction factor applied. DESIGN: An algorithm to detect changes in SCr that in turn affect eGFR calculation method was developed. It compares the mapping of SCr values on to eGFR values across a time series of paired eGFR and SCr measurements. SETTING: Routinely collected primary care data from 20,000 @entity0 with the richest renal function data from the quality improvement in @entity2 trial. RESULTS: The algorithm identified a change in eGFR calculation method in 114 (90%) of the 127 included practices. This change was identified in 4736 (23.7%) @entity0 time series analysed. This change in calibration method was found to cause a significant step change in the reported eGFR values, producing a systematic bias. The eGFR values could not be recalibrated by applying the Modification of Diet in @entity1 equation to the laboratory reported SCr values. CONCLUSIONS: This algorithm can identify laboratory changes in eGFR calculation methods and changes in SCr assay. Failure to account for these changes may misconstrue renal function changes over time. Researchers using routine eGFR data should account for these effects.

title: Improving the measurement of longitudinal change in renal function: automated detection of changes in laboratory XXXX assay.

answer: @entity3


abstract: PURPOSE: @entity6 is a complication of head and neck radiotherapy, with a difficult resolution and no well-established treatment. The disease progression can cause important loss on @entity0 's quality of life after @entity1 treatment. The options for treatment are limited and include clinical monitoring, prescription, or surgical procedures. As an alternative for bone @entity2 treatment, a combination of drugs, @entity4 and @entity5 , can be used. Studies have shown that this combination significantly reduces chronic radiotherapy damage. The article reports successful treatment with this prescription protocol. METHODS: We report three cases of @entity0 referred to the Service of Oral and Maxillofacial Surgery at Erasto Gaertner Hospital, in Curitiba, Brazil. They were submitted to radiotherapy for the treatment of @entity3 and later developed @entity6 . They were treated with the combination @entity4 and @entity5 . RESULTS: All @entity0 achieved complete remission in less than 1  year, with complete healing of bone exposure and without clinical symptoms. CONCLUSIONS: This results show that this combination of drugs is beneficial in cases of bone @entity2 induced by radiation, avoiding more aggressive treatments and reducing morbidity.

title: Tissue repair in XXXX using @entity4 and @entity5 --report of three cases.

answer: @entity6


abstract: PURPOSE: @entity6 is a complication of head and neck radiotherapy, with a difficult resolution and no well-established treatment. The disease progression can cause important loss on @entity0 's quality of life after @entity1 treatment. The options for treatment are limited and include clinical monitoring, prescription, or surgical procedures. As an alternative for bone @entity2 treatment, a combination of drugs, @entity4 and @entity5 , can be used. Studies have shown that this combination significantly reduces chronic radiotherapy damage. The article reports successful treatment with this prescription protocol. METHODS: We report three cases of @entity0 referred to the Service of Oral and Maxillofacial Surgery at Erasto Gaertner Hospital, in Curitiba, Brazil. They were submitted to radiotherapy for the treatment of @entity3 and later developed @entity6 . They were treated with the combination @entity4 and @entity5 . RESULTS: All @entity0 achieved complete remission in less than 1  year, with complete healing of bone exposure and without clinical symptoms. CONCLUSIONS: This results show that this combination of drugs is beneficial in cases of bone @entity2 induced by radiation, avoiding more aggressive treatments and reducing morbidity.

title: Tissue repair in @entity6 using XXXX and @entity5 --report of three cases.

answer: @entity4


abstract: PURPOSE: @entity6 is a complication of head and neck radiotherapy, with a difficult resolution and no well-established treatment. The disease progression can cause important loss on @entity0 's quality of life after @entity1 treatment. The options for treatment are limited and include clinical monitoring, prescription, or surgical procedures. As an alternative for bone @entity2 treatment, a combination of drugs, @entity4 and @entity5 , can be used. Studies have shown that this combination significantly reduces chronic radiotherapy damage. The article reports successful treatment with this prescription protocol. METHODS: We report three cases of @entity0 referred to the Service of Oral and Maxillofacial Surgery at Erasto Gaertner Hospital, in Curitiba, Brazil. They were submitted to radiotherapy for the treatment of @entity3 and later developed @entity6 . They were treated with the combination @entity4 and @entity5 . RESULTS: All @entity0 achieved complete remission in less than 1  year, with complete healing of bone exposure and without clinical symptoms. CONCLUSIONS: This results show that this combination of drugs is beneficial in cases of bone @entity2 induced by radiation, avoiding more aggressive treatments and reducing morbidity.

title: Tissue repair in @entity6 using @entity4 and XXXX --report of three cases.

answer: @entity5


abstract: Differential diagnosis between @entity6 ( @entity6 ) @entity3 ( @entity3 ) @entity2 is essential due to significantly different prognoses and therapeutic options. Therefore, clinical characteristics of @entity0 with biopsy-proven @entity2 were investigated to differentiate @entity6 from @entity4 . From September 2006 to May 2014, 46 @entity0 were confirmed to have @entity2 ( @entity6 , n   =   28; @entity3 , n   =   18) in our institute. The median age of @entity0 with @entity6 @entity4 was 78  years (range 61-90) with 27 (96  %) males, while that of @entity0 with @entity4 was 66 (range 52-76) with 12 (67  %) males. There were no statistically significant differences in echocardiographic findings regarding left ventricular (LV) systolic function or @entity1 between the two groups. Interestingly, serum @entity5 ( @entity5 ) levels in @entity0 with @entity4 were significantly higher than those in @entity6 @entity4 @entity0 . In contrast, the LV wall was significantly thicker in @entity0 with @entity6 @entity4 than in those with @entity4 . Therefore, the ratio of @entity5 to LV mass index (LVMI) at presentation in @entity4 @entity0 was significantly higher than that in @entity6 @entity0 (6.7 vs 2.9, p   =   0.0006). A @entity5 -LVMI ratio of less than 3.5 had a diagnostic sensitivity and specificity for @entity6 @entity4 of 71 and 83  %, respectively. One-year overall survival was 88.7  % in the @entity0 with @entity6 @entity4 and 23.7  % in the @entity0 with @entity4 . Our analysis indicates that the @entity5 -LVMI ratio, as well as age and sex, may be useful parameters for distinguishing @entity6 from @entity2 .

title: Clinical and echocardiographic characteristics for differentiating between XXXX -related and light-chain @entity2 .

answer: @entity6


abstract: Differential diagnosis between @entity6 ( @entity6 ) @entity3 ( @entity3 ) @entity2 is essential due to significantly different prognoses and therapeutic options. Therefore, clinical characteristics of @entity0 with biopsy-proven @entity2 were investigated to differentiate @entity6 from @entity4 . From September 2006 to May 2014, 46 @entity0 were confirmed to have @entity2 ( @entity6 , n   =   28; @entity3 , n   =   18) in our institute. The median age of @entity0 with @entity6 @entity4 was 78  years (range 61-90) with 27 (96  %) males, while that of @entity0 with @entity4 was 66 (range 52-76) with 12 (67  %) males. There were no statistically significant differences in echocardiographic findings regarding left ventricular (LV) systolic function or @entity1 between the two groups. Interestingly, serum @entity5 ( @entity5 ) levels in @entity0 with @entity4 were significantly higher than those in @entity6 @entity4 @entity0 . In contrast, the LV wall was significantly thicker in @entity0 with @entity6 @entity4 than in those with @entity4 . Therefore, the ratio of @entity5 to LV mass index (LVMI) at presentation in @entity4 @entity0 was significantly higher than that in @entity6 @entity0 (6.7 vs 2.9, p   =   0.0006). A @entity5 -LVMI ratio of less than 3.5 had a diagnostic sensitivity and specificity for @entity6 @entity4 of 71 and 83  %, respectively. One-year overall survival was 88.7  % in the @entity0 with @entity6 @entity4 and 23.7  % in the @entity0 with @entity4 . Our analysis indicates that the @entity5 -LVMI ratio, as well as age and sex, may be useful parameters for distinguishing @entity6 from @entity2 .

title: Clinical and echocardiographic characteristics for differentiating between @entity6 -related and light-chain XXXX .

answer: @entity2


abstract: BACKGROUND AND OBJECTIVE: Concerns about the harms of intravenous alteplase (recombinant @entity3 ) continue to deter physicians from treating @entity0 with acute @entity2 with the only drug proven to positively impact outcomes and reduce disability. Recent literature indicates an increase in mortality with alteplase within 7 days, an effect that does not persist from 3 months onwards. The objective of this meta-analysis was to pool mortality estimates from randomized controlled clinical trials (RCTs) at 7 days, 30 days, 90 days, and 6 months after @entity1 onset. METHODS: PubMed, Embase, Scopus, CENTRAL, and clinicaltrials.gov were searched through to April 2014, using "hedges" for @entity3 , acute @entity2 , and placebo. Two independent authors abstracted data and assessed study quality. Data were pooled using Dersimonian and Laird's random effects model. RESULTS: Eleven RCTs (n = 6905) were included in the final analysis. Two authors independently performed study selection and data abstraction. There was no publication bias and total variance attributable to heterogeneity was not significant (I(2) < 50%) at any time point. There was no difference in mortality between alteplase and placebo groups at any time point. Trials that randomized @entity0 beyond 3 h (excluded @entity0 within the 3-h window) did not drive the mortality difference seen at any time point. Exclusion sensitivity analysis revealed that exclusion of the NINDS trial rendered the 7-day difference significant towards increased mortality with alteplase. Quality adjustment did not alter the results. CONCLUSION: Intravenous alteplase did not impact mortality in @entity0 with acute @entity2 at any of the measured time points up to 6 months (i.e., there was no increase in the risk of death with alteplase). Therefore, intravenous alteplase should be given to all eligible @entity0 with acute @entity2 to improve long-term neurologic outcomes. The effects of alteplase on early survival are more complex than previously understood.

title: Intravenous Recombinant @entity3 Does Not Impact Mortality in Acute XXXX at Any Time Point up to 6 Months: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.

answer: @entity2


abstract: BACKGROUND AND OBJECTIVE: Concerns about the harms of intravenous alteplase (recombinant @entity3 ) continue to deter physicians from treating @entity0 with acute @entity2 with the only drug proven to positively impact outcomes and reduce disability. Recent literature indicates an increase in mortality with alteplase within 7 days, an effect that does not persist from 3 months onwards. The objective of this meta-analysis was to pool mortality estimates from randomized controlled clinical trials (RCTs) at 7 days, 30 days, 90 days, and 6 months after @entity1 onset. METHODS: PubMed, Embase, Scopus, CENTRAL, and clinicaltrials.gov were searched through to April 2014, using "hedges" for @entity3 , acute @entity2 , and placebo. Two independent authors abstracted data and assessed study quality. Data were pooled using Dersimonian and Laird's random effects model. RESULTS: Eleven RCTs (n = 6905) were included in the final analysis. Two authors independently performed study selection and data abstraction. There was no publication bias and total variance attributable to heterogeneity was not significant (I(2) < 50%) at any time point. There was no difference in mortality between alteplase and placebo groups at any time point. Trials that randomized @entity0 beyond 3 h (excluded @entity0 within the 3-h window) did not drive the mortality difference seen at any time point. Exclusion sensitivity analysis revealed that exclusion of the NINDS trial rendered the 7-day difference significant towards increased mortality with alteplase. Quality adjustment did not alter the results. CONCLUSION: Intravenous alteplase did not impact mortality in @entity0 with acute @entity2 at any of the measured time points up to 6 months (i.e., there was no increase in the risk of death with alteplase). Therefore, intravenous alteplase should be given to all eligible @entity0 with acute @entity2 to improve long-term neurologic outcomes. The effects of alteplase on early survival are more complex than previously understood.

title: Intravenous Recombinant XXXX Does Not Impact Mortality in Acute @entity2 at Any Time Point up to 6 Months: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials.

answer: @entity3


abstract: PURPOSE: Based on preclinical evidence of synergistic activity between @entity11 and @entity5 inhibitors in @entity7 ( @entity7 ), we evaluated the safety and efficacy of @entity13 , a @entity12 inhibitor, plus @entity9 in @entity0 with previously treated advanced @entity7 . EXPERIMENTAL DESIGN: In this single-arm phase II trial, eligible @entity0 received the combination of @entity9 100 mg plus @entity13 100 mg daily in 3-week cycles. Study assessments included measurement of clinical outcomes, with a primary endpoint of overall survival, and exploration of potential molecular predictors of treatment benefit. RESULTS: 46 @entity0 were enrolled and received a median of 2 cycles (range, 1-7). While no objective responses were observed, 19 @entity0 (41%) showed evidence of stable disease for >= 6 weeks, and 13/34 @entity0 (38%) had a CA19-9 decline >= 50%. Median progression-free survival was 1.9 months (95% CI, 1.4-3.3 months), with a median OS of 7.3 months (95% CI, 5.2-8.0 months). Common adverse events included @entity8 , @entity2 , and @entity3 / @entity4 . @entity0 with @entity1 exhibiting an epithelial phenotype (demonstrated by high level of @entity10 expression) were more likely to be sensitive to study treatment. Tumor-derived DNA was detectable in plasma from the majority of @entity0 using next-generation digital DNA sequencing, and its relative abundance correlated with @entity1 burden. CONCLUSIONS: A therapeutic strategy of dual targeted inhibition of the @entity11 and @entity5 pathways shows modest antitumor activity in @entity6 . Specific molecular subtypes may derive greatest benefit from this combination. Further exploration, both with more potent @entity11 inhibitors and in molecularly enriched @entity0 subsets, is warranted.

title: A MULTICENTER, OPEN-LABEL PHASE II CLINICAL TRIAL OF COMBINED @entity11 PLUS XXXX INHIBITION FOR CHEMOTHERAPY-REFRACTORY ADVANCED PANCREATIC ADENOCARCINOMA.

answer: @entity5


abstract: PURPOSE: Based on preclinical evidence of synergistic activity between @entity11 and @entity5 inhibitors in @entity7 ( @entity7 ), we evaluated the safety and efficacy of @entity13 , a @entity12 inhibitor, plus @entity9 in @entity0 with previously treated advanced @entity7 . EXPERIMENTAL DESIGN: In this single-arm phase II trial, eligible @entity0 received the combination of @entity9 100 mg plus @entity13 100 mg daily in 3-week cycles. Study assessments included measurement of clinical outcomes, with a primary endpoint of overall survival, and exploration of potential molecular predictors of treatment benefit. RESULTS: 46 @entity0 were enrolled and received a median of 2 cycles (range, 1-7). While no objective responses were observed, 19 @entity0 (41%) showed evidence of stable disease for >= 6 weeks, and 13/34 @entity0 (38%) had a CA19-9 decline >= 50%. Median progression-free survival was 1.9 months (95% CI, 1.4-3.3 months), with a median OS of 7.3 months (95% CI, 5.2-8.0 months). Common adverse events included @entity8 , @entity2 , and @entity3 / @entity4 . @entity0 with @entity1 exhibiting an epithelial phenotype (demonstrated by high level of @entity10 expression) were more likely to be sensitive to study treatment. Tumor-derived DNA was detectable in plasma from the majority of @entity0 using next-generation digital DNA sequencing, and its relative abundance correlated with @entity1 burden. CONCLUSIONS: A therapeutic strategy of dual targeted inhibition of the @entity11 and @entity5 pathways shows modest antitumor activity in @entity6 . Specific molecular subtypes may derive greatest benefit from this combination. Further exploration, both with more potent @entity11 inhibitors and in molecularly enriched @entity0 subsets, is warranted.

title: A MULTICENTER, OPEN-LABEL PHASE II CLINICAL TRIAL OF COMBINED XXXX PLUS @entity5 INHIBITION FOR CHEMOTHERAPY-REFRACTORY ADVANCED PANCREATIC ADENOCARCINOMA.

answer: @entity11


abstract: UNASSIGNED: The @entity6 reflex to an intense acoustic pulse stimulus is attenuated if the pulse stimulus is shortly preceded by a weak non-startling prepulse stimulus. This attenuation of the @entity6 reflex represents a form of pre-attentional sensory gating known as prepulse inhibition (PPI). Although PPI does not require learning, its expression is regulated by higher cognitive processes. @entity2 have been detected in several @entity4 conditions including @entity5 where they co-exist with @entity3 . A potential link between PPI expression and cognitive performance has therefore been suggested such that poor PPI may predict, or may be mechanistically linked to, overt @entity3 . A positive relationship between PPI and strategy formation, planning efficiency, and execution speed has been observed in healthy @entity0 . However, parallel studies in healthy animals are rare. It thus remains unclear what cognitive domains may be associated with, or orthogonal to, sensory gating in the form of PPI in healthy animals. The present study evaluated a potential link between the magnitude of PPI and spatial memory performance by comparing two subgroups of animals differing substantially in baseline PPI expression (low-PPI vs high-PPI) within a homogenous cohort of 100 male adult C57BL/6 @entity1 . Assessment of spatial reference memory in the Morris water maze and spatial recognition memory in the Y-maze failed to reveal any difference between low-PPI and high-PPI subjects. These negative findings contrast with our previous reports that individual difference in PPI correlated with @entity7 performance in C57BL/6 @entity1 .

title: Individual difference in prepulse inhibition does not predict spatial learning and memory performance in C57BL/6 XXXX .

answer: @entity1


abstract: CONTEXT: @entity3 is a @entity2 and increased mortality. The incidence and prevalence of @entity3 worldwide is not well known. OBJECTIVE: To gather information on @entity0 diagnosed with acromegly in Iceland over 59  years. DESIGN: Information was retrospectively gathered about @entity0 diagnosed with @entity3 from 1955 through 2013. Incidence was calculated from the total Icelandic population. SETTING/ @entity0 : Information was gathered from medical records at Landspitali National University Hospital, Iceland, housing the only endocrine department in the country, at the largest hospital outside of Reykjavik (Sj  krah  si      Akureyri, Akureyri Hospital) and the largest private outpatient clinic in Reykjavik, where some of the @entity0 received follow-up care. Further, information on @entity0 were sought from all endocrinologists treating adult @entity0 in Iceland. All @entity0 diagnosed with @entity3 during the study period were included. RESULTS: Fifty-two @entity0 (32 @entity0 ) were diagnosed during the study period. The average age at diagnosis was 44.5  years. Nine @entity0 had died. Symptoms had been present for more than 3  years in most cases. Twenty-five @entity0 had @entity1 (48  %). Follow up information was available for 48 @entity0 , 63  % were considered cured after treatment. CONCLUSIONS: The incidence of @entity3 in Iceland during the study period was much higher than earlier reports have indicated. During the last 9  years of the study 7.7 @entity0 were diagnosed per million per year. At diagnosis, 38  % had developed @entity1 and 10  % were diagnosed during follow up. This indicates the importance of @entity4 in the aetiology of @entity1 .

title: The incidence and prevalence of XXXX , a nationwide study from 1955 through 2013.

answer: @entity3


abstract: INTRODUCTION: @entity3 ( @entity3 ) is a prototypic @entity6 attributable to complement dysregulation. In the absence of complement inhibition, progressive clinical deterioration occurs. The authors postulated that a biopsy of normal skin could corroborate the diagnosis of @entity3 through the demonstration of vascular deposits of C5b-9. MATERIALS AND METHODS: Biopsies of normal skin from 22 @entity0 with and without @entity3 were processed for routine light microscopy and immunofluorescent studies. An assessment was made for vascular C5b-9 deposition immunohistochemically and by immunofluorescence. The biopsies were obtained primarily from the forearm and/or deltoid. RESULTS: @entity0 with classic features of @entity3 showed insidious microvascular changes including loose luminal platelet thrombi, except in 2 @entity0 in whom a striking @entity1 was apparent in biopsied digital @entity2 . Extensive microvascular deposits of the membrane attack complex/C5b-9 were identified, excluding 1 @entity0 in whom eculizumab was initiated before biopsy. In 5 of the 7 @entity0 where follow-up was available, the @entity0 exhibited an excellent treatment response to eculizumab. @entity0 without diagnostic clinical features of @entity3 failed to show significant vascular deposits of complement, except 2 @entity0 with @entity4 including 1 in whom a @entity5 mutation was identified. CONCLUSIONS: In a clinical setting where @entity3 is an important diagnostic consideration, extensive microvascular deposition of C5b-9 supports the diagnosis of either @entity3 or a subset of @entity4 @entity0 with concomitant complement dysregulation; significant vascular C5b-9 deposition predicts clinical responsiveness to eculizumab.

title: Role of the skin biopsy in the diagnosis of XXXX .

answer: @entity3


abstract: UNASSIGNED: Maladaptive social interaction and its related psychopathology have been highlighted in psychiatry especially among younger generations. In Japan, novel expressive forms of @entity1 phenomena such as " @entity2 " and "hikikomori" (a syndrome of severe social withdrawal lasting for at least six months) have been reported especially among young @entity0 . Economic games such as the trust game have been utilized to evaluate real-world interpersonal relationships as a novel candidate for @entity1 evaluations. To investigate the relationship between trusting behaviors and various psychometric scales, we conducted a trust game experiment with eighty-one Japanese university students as a pilot study. @entity0 made a risky financial decision about whether to trust each of 40 photographed partners. @entity0 then answered a set of questionnaires with seven scales including the Lubben Social Network Scale (LSNS)-6 and the @entity0 Health Questionnaire (PHQ)-9. Consistent with previous research, male @entity0 trusted partners more than female @entity0 . Regression analysis revealed that LSNS-family (perceived support from family) for male @entity0 , and item 8 of PHQ-9 (subjective @entity3 ) for female @entity0 were associated with @entity0 ' trusting behaviors. Consistent with claims by social scientists, our data suggest that, for males, support from family was negatively associated with cooperative behavior toward non-family members. Females with higher subjective agitation (and/or retardation) gave less money toward males and high attractive females, but not toward low attractive females in interpersonal relationships. We believe that our data indicate the possible impact of economic games in @entity1 research and clinical practice, and validation in clinical samples including @entity2 and hikikomori should be investigated.

title: Relationship between Trusting Behaviors and Psychometrics Associated with Social Network and XXXX among Young Generation: A Pilot Study.

answer: @entity2


abstract: OBJECTIVE: To investigate the genetic contribution of @entity1 gene polymorphisms on the disease course and therapeutic response in @entity0 with @entity2 ( @entity2 ). METHODS: 74 Caucasian @entity0 with @entity2 were recruited with a control group of 77 healthy @entity0 . DNA was extracted for analysis of @entity1 gene promoter polymorphisms at positions -163, -244, -238, -376, and -308. RESULTS: No SNPs at position -163 were observed, while we observed only SNPs at positions -244 and -376 in the controls. No differences were observed in the prevalence of SNPs at -238 and -308 between @entity2 and controls. In @entity2 @entity0 no significant differences were observed between the -238 and @entity3 genotypes and different disease phenotypes. We observed a significant lower disease activity expressed in the carriers of -308 GG genotype with respect to GA and AA genotypes after 6 (p = 0.008 and p = 0.013, respectively) and 12 months of disease (p = 0.02 and p = 0.08, respectively). Also the -238 GG genotypes showed a better disease course after 12 months of disease. Moreover, the -238/-308 GG genotypes presented the higher reduction of disease activity both after 6 (p < 0.01 vs GA and p < 0.01 vs AA) and 12 months from baseline (p < 0.01 vs GA and p < 0.01 vs AA). After 12 months of biologic therapy, a significant higher disease activity was observed in @entity0 with genotype -308 AA respect to both GA (p = 0.012) and GG (p = 0.016). CONCLUSIONS: @entity2 @entity0 carrying the @entity1 -308 GA/AA and -238 GA genotypes are associated with a worse prognosis and with a lower response to anti- @entity1 drugs.

title: XXXX gene polymorphisms and @entity2 : Influence on disease outcome and therapeutic response.

answer: @entity1


abstract: OBJECTIVE: To investigate the genetic contribution of @entity1 gene polymorphisms on the disease course and therapeutic response in @entity0 with @entity2 ( @entity2 ). METHODS: 74 Caucasian @entity0 with @entity2 were recruited with a control group of 77 healthy @entity0 . DNA was extracted for analysis of @entity1 gene promoter polymorphisms at positions -163, -244, -238, -376, and -308. RESULTS: No SNPs at position -163 were observed, while we observed only SNPs at positions -244 and -376 in the controls. No differences were observed in the prevalence of SNPs at -238 and -308 between @entity2 and controls. In @entity2 @entity0 no significant differences were observed between the -238 and @entity3 genotypes and different disease phenotypes. We observed a significant lower disease activity expressed in the carriers of -308 GG genotype with respect to GA and AA genotypes after 6 (p = 0.008 and p = 0.013, respectively) and 12 months of disease (p = 0.02 and p = 0.08, respectively). Also the -238 GG genotypes showed a better disease course after 12 months of disease. Moreover, the -238/-308 GG genotypes presented the higher reduction of disease activity both after 6 (p < 0.01 vs GA and p < 0.01 vs AA) and 12 months from baseline (p < 0.01 vs GA and p < 0.01 vs AA). After 12 months of biologic therapy, a significant higher disease activity was observed in @entity0 with genotype -308 AA respect to both GA (p = 0.012) and GG (p = 0.016). CONCLUSIONS: @entity2 @entity0 carrying the @entity1 -308 GA/AA and -238 GA genotypes are associated with a worse prognosis and with a lower response to anti- @entity1 drugs.

title: @entity1 gene polymorphisms and XXXX : Influence on disease outcome and therapeutic response.

answer: @entity2


abstract: BACKGROUND: According to the World Health Organization (WHO) report released in 2000, about 121 million @entity0 worldwide suffer from @entity2 . The @entity2 ( @entity2 ) among @entity1 ( @entity1 ) @entity0 is one of the most common @entity3 experienced during life. @entity1 @entity0 who simultaneously suffer from @entity2 have reported more severe symptoms of disease and slower adaptation to new conditions, which ultimately increase the cost of treatment. OBJECTIVES: The aim of this study was to assess the effectiveness of progressive muscle relaxation therapy (PMRT) as an adjunctive therapy for reducing level of @entity2 for @entity1 @entity0 . MATERIALS AND METHODS: This research had the randomized controlled trial design with pre and posttest. Thirty female @entity0 based on criteria of @entity1 and @entity2 , were selected from the @entity1 Society of Shiraz, Iran. Beck Depression Inventory (BDI-II) was administered at pre and posttest. The @entity0 were randomly allocated to two groups (experimental and control). Twelve sessions of PMRT using Bernstein and Borkovec's method were held for the experimental group. Levin's test, covariance and ANOVA with repeated measures were used for data analysis. RESULTS: Experimental and control groups were compared before and after treatment. Analysis of covariance showed that seven levels of @entity2 decreased in the experimental group and analysis of repeated measure showed that 49% of the changes were related to PMRT. CONCLUSION: According to the results, PMRT is effective in reducing @entity2 . This therapy enables @entity0 to reach relaxation quickly, and thus can cope with @entity2 reactions effectively.

title: A Fresh Look at the Potential Mechanisms of Progressive Muscle Relaxation Therapy on Depression in Female @entity0 With XXXX .

answer: @entity1


abstract: BACKGROUND: According to the World Health Organization (WHO) report released in 2000, about 121 million @entity0 worldwide suffer from @entity2 . The @entity2 ( @entity2 ) among @entity1 ( @entity1 ) @entity0 is one of the most common @entity3 experienced during life. @entity1 @entity0 who simultaneously suffer from @entity2 have reported more severe symptoms of disease and slower adaptation to new conditions, which ultimately increase the cost of treatment. OBJECTIVES: The aim of this study was to assess the effectiveness of progressive muscle relaxation therapy (PMRT) as an adjunctive therapy for reducing level of @entity2 for @entity1 @entity0 . MATERIALS AND METHODS: This research had the randomized controlled trial design with pre and posttest. Thirty female @entity0 based on criteria of @entity1 and @entity2 , were selected from the @entity1 Society of Shiraz, Iran. Beck Depression Inventory (BDI-II) was administered at pre and posttest. The @entity0 were randomly allocated to two groups (experimental and control). Twelve sessions of PMRT using Bernstein and Borkovec's method were held for the experimental group. Levin's test, covariance and ANOVA with repeated measures were used for data analysis. RESULTS: Experimental and control groups were compared before and after treatment. Analysis of covariance showed that seven levels of @entity2 decreased in the experimental group and analysis of repeated measure showed that 49% of the changes were related to PMRT. CONCLUSION: According to the results, PMRT is effective in reducing @entity2 . This therapy enables @entity0 to reach relaxation quickly, and thus can cope with @entity2 reactions effectively.

title: A Fresh Look at the Potential Mechanisms of Progressive Muscle Relaxation Therapy on Depression in Female XXXX With @entity1 .

answer: @entity0


abstract: INTRODUCTION: @entity4 ( @entity4 ) are collectively the third most common @entity5 , surpassed only by prostate and @entity2 . Cure rates for @entity4 are related to @entity0 grade and stage; therefore, diagnostic methods for early detection and new therapeutic modalities are of paramount importance. Epigenetics can be defined as inherited modifications in gene expression that are not encoded in the DNA sequence itself. Epigenetics may play an important role in the pursuit of early diagnosis, accurate prognostication and identification of new therapeutic targets. MATERIAL AND METHODS: We used PubMed to conduct a comprehensive search of the English medical literature using search terms including epigenetics, DNA methylation, histone modification, microRNA regulation (miRNA) and @entity4 . In this review, we discuss the potential application of epigenetics in the diagnosis, prognosis and treatment of @entity3 . RESULTS: During the last decade, many different types of epigenetic alterations of DNA have been found to be associated with @entity3 . This has led to the research of the diagnostic and prognostic implications of these changes in @entity1 as well as to the development of novel drugs to target these changes, with the aim of achieving a survival benefit. CONCLUSIONS: Epigenetics has become a promising field in @entity0 research. The potential to achieve early detection and accurate prognostication in @entity3 might be feasible through the application of epigenetics. The possibility to reverse these epigenetic changes with new therapeutic agents motivates researchers to continue pursuing better treatment options for @entity3 and other @entity0 .

title: The role of epigenetics in XXXX .

answer: @entity1


abstract: Intrinsically disordered proteins (IDPs) are proteins that lack secondary and/or tertiary structure under physiological conditions. These proteins are very abundant in eukaryotic proteomes and play crucial roles in all molecular mechanisms underlying the response to environmental challenges. In plants, different IDPs involved in stress response have been identified and characterized. Nevertheless, a comprehensive evaluation of @entity0 in plant proteomes under abiotic or biotic stresses is not available so far. In the present work the transcriptome dataset of strawberry (Fragaria X ananassa) fruits interacting with the fungal pathogen Colletotrichum acutatum was actualized onto the woodland strawberry (Fragaria vesca) genome. The obtained cDNA sequences were translated into protein sequences, which were subsequently subjected to disorder analysis. The results, providing the first estimation of disorder abundance associated to plant @entity1 , showed that the proteome activated in the strawberry red fruit during the active fungal propagation is remarkably depleted in disorder. On the other hand, in the resistant white fruit, no significant @entity0 is observed in the proteins expressed in response to @entity2 . Four representative proteins, FvSMP, FvPRKRIP, FvPCD-4 and FvFAM32A-like, predicted as mainly disordered and never experimentally characterized before, were isolated, and the absence of structure was validated at the secondary and tertiary level using circular dichroism and differential scanning fluorimetry. Their quaternary structure was also established using light scattering. The results are discussed considering the role of @entity0 in plant defense.

title: Unfoldome variation upon plant-pathogen interactions: strawberry XXXX by Colletotrichum acutatum.

answer: @entity1


abstract: PURPOSE: To evaluate choroidal thickness, macular thickness, and peripapillary retinal nerve fiber layer (RNFL) thickness in @entity0 compared to fellow and normal control eyes using high-definition spectral-domain optical coherence tomography (SD- @entity5 ). METHODS: Fifty-four without any systemic problem and @entity2 participated in this prospective study. Inclusion criteria included individuals older than 18 years with @entity4 . @entity3 , @entity1 ( @entity1 ), and RNFL thickness were measured by using enhanced depth imaging SD- @entity5 . The choroidal thickness was measured at the fovea and at 500   m intervals from the foveal center in both temporal and nasal directions. Axial length measurements of the cases were also recorded. RESULTS: Mean peripapillary RNFL thickness of the amblyopic, fellow, and control eyes was 107.5    15.5   m, 109.3    12.7   m, and 108.8    8.6   m, respectively (p = 0.343). The average @entity1 was 231.7    14.7   m in @entity0 , 232.5    15.7  m in fellow eyes, and 230.8    14.8   m in control eyes (p = 0.599). Mean subfoveal choroidal thickness was significantly greater in the @entity0 than in the fellow and control eyes (396.3    104.3   m, 361.0    103.9   m, 390.6    91.7   m). Mean axial measurement in @entity0 was 22.7    1.3 mm (20.5-26.1), in fellow eyes 23.1    0.9 mm (20.9-25.0), and in control eyes 23.3    0.9 mm. CONCLUSIONS: In adults with @entity4 , subfoveal, temporal, and nasal choroidal thickness of @entity0 are significantly thicker than in fellow eyes. However, no significant differences in peripapillary RNFL thickness or @entity1 were found between amblyopic and fellow or control eyes.

title: Choroidal and peripapillary retinal nerve fiber layer thickness in adults with XXXX .

answer: @entity4


abstract: INTRODUCTION: Overweight and @entity1 are global public health problems because of their effect on individuals, families and communities. The objective of this study was to describe the profile of overweight and @entity1 amongst adult out @entity0 in Uyo in the @entity3 Delta region of Nigeria. METHOD: This was a cross-sectional descriptive study done between October 2011 and March 2012. Using a systematic sampling technique, 584 subjects aged 18-65 years were recruited; data were collected with a structured questionnaire. Subjects were measured for height, weight, waist and hip circumferences. Body mass index (BMI) and waist-hip ratio (WHR) were calculated. Subjects with a BMI of 25.0 kg/m2 - 29.9 kg/m2 were regarded as being overweight whilst a BMI of > 30.0 kg/m2 was regarded as @entity1 . Subjects with a WHR of > 0.90 for @entity0 or > 0.85 for @entity0 were regarded as having abnormal WHR. RESULTS: Of the 584 subjects, 196 (36.6%) were @entity0 and 388 (66.4%) @entity0 . The mean age for @entity0 and @entity0 was 43.3    17.8 years and 50.2    13.6 years, respectively. The prevalence of overweight amongst @entity0 was 39.8% versus 31.7% for @entity0 ; @entity1 in @entity0 was 28.0% versus 52.0% in @entity0 . Overweight and @entity1 were more prevalent in subjects aged 25-54 years and amongst married subjects. There was a significant relationship between @entity1 and television viewing (p = 0.003). @entity2 (p = 0.008) and @entity4 (p = 0.043) were more prevalent amongst the @entity1 than the non- @entity1 subjects. CONCLUSION: Overweight and @entity1 are now common in our environment. There is therefore a need for more public education about the health consequences of big body size.

title: Overweight and @entity1 profiles in XXXX Delta Region, Nigeria.

answer: @entity3


abstract: INTRODUCTION: Overweight and @entity1 are global public health problems because of their effect on individuals, families and communities. The objective of this study was to describe the profile of overweight and @entity1 amongst adult out @entity0 in Uyo in the @entity3 Delta region of Nigeria. METHOD: This was a cross-sectional descriptive study done between October 2011 and March 2012. Using a systematic sampling technique, 584 subjects aged 18-65 years were recruited; data were collected with a structured questionnaire. Subjects were measured for height, weight, waist and hip circumferences. Body mass index (BMI) and waist-hip ratio (WHR) were calculated. Subjects with a BMI of 25.0 kg/m2 - 29.9 kg/m2 were regarded as being overweight whilst a BMI of > 30.0 kg/m2 was regarded as @entity1 . Subjects with a WHR of > 0.90 for @entity0 or > 0.85 for @entity0 were regarded as having abnormal WHR. RESULTS: Of the 584 subjects, 196 (36.6%) were @entity0 and 388 (66.4%) @entity0 . The mean age for @entity0 and @entity0 was 43.3    17.8 years and 50.2    13.6 years, respectively. The prevalence of overweight amongst @entity0 was 39.8% versus 31.7% for @entity0 ; @entity1 in @entity0 was 28.0% versus 52.0% in @entity0 . Overweight and @entity1 were more prevalent in subjects aged 25-54 years and amongst married subjects. There was a significant relationship between @entity1 and television viewing (p = 0.003). @entity2 (p = 0.008) and @entity4 (p = 0.043) were more prevalent amongst the @entity1 than the non- @entity1 subjects. CONCLUSION: Overweight and @entity1 are now common in our environment. There is therefore a need for more public education about the health consequences of big body size.

title: Overweight and XXXX profiles in @entity3 Delta Region, Nigeria.

answer: @entity1


abstract: BACKGROUND: Currently there is controversy surrounding the optimal way to treat @entity0 with @entity5 in the @entity7 . Adjuvant therapies carry possible benefits of improved curative results, but there is uncertainty in which @entity0 should receive adjuvant therapy. There are concerns about giving @entity3 to a whole population for the benefit of only a subset. We hypothesized that making @entity6 treatment decisions using genomics-based risk prediction estimates would improve @entity2 and quality of life outcomes. METHODS: We developed a state-transition model to simulate outcomes over a 10 year horizon for a cohort of @entity6 @entity0 . Outcomes included @entity2 progression rates at 5 and 10 years, overall survival, and quality-adjusted survival with reductions for treatment, side effects, and @entity2 stage. We compared outcomes using population-level versus individual-level risk of @entity2 progression, and for genomics-based care versus usual care treatment recommendations. RESULTS: Cancer progression outcomes, expected life-years (LYs), and expected quality-adjusted life-years (QALYs) were significantly different when individual genomics-based @entity2 progression risk estimates were used in place of population-level risk estimates. Use of the genomic classifier to guide treatment decisions provided small, but statistically significant, improvements in model outcomes. We observed an additional 0.03 LYs and 0.07 QALYs, a 12% relative increase in the 5-year recurrence-free survival probability, and a 4% relative reduction in the 5-year probability of @entity1 or @entity4 . CONCLUSIONS: The use of genomics-based risk prediction to guide treatment decisions may improve outcomes for @entity5 @entity0 . This study offers a framework for individualized decision analysis, and can be extended to incorporate a wide range of personal attributes to enable delivery of @entity0 -centered tools for informed decision-making.

title: Evaluating the Clinical Impact of a Genomic Classifier in XXXX Using Individualized Decision Analysis.

answer: @entity5


abstract: BACKGROUND: In Tanzania, a country of 42 million, access to oral @entity3 is rare. AIM: To demonstrate the effectiveness of palliative care teams in reducing @entity0 ' @entity2 and  in increasing other positive life qualities in the absence of @entity3 ; and to document the  psychological burden experienced by their clinical providers, trained in @entity3 delivery, as  they observed their @entity0 suffering and in extreme @entity2 . SETTING: One hundred and forty-fie @entity1 @entity0 were included from 13 rural hospitals  spread across Tanzania. METHOD: A mixed method study beginning with a retrospective quantitative analysis of @entity1  @entity0 who were administered the APCA African POS tool four times. Bivariate analyses  of the scores at time one and four were compared across the domains. The qualitative arm  included an analysis of interviews with six nurses, each with more than fie years' palliative  care experience and no access to strong opioids. RESULTS: @entity0 and their family caregivers identifid statistically signifiant (p < 0.001)  improvements in all of the domains. Thematic analysis of nurse interviews described the  @entity0 and family benefis from palliative care but also their great distress when 'bad  cases' arose who would likely benefi only from oral @entity3 . CONCLUSION: @entity0 living with chronic @entity1 who receive palliative care  experience profound physical, spiritual and emotional benefis even without oral @entity3 .  These results demonstrate the need for continued advocacy to increase the availability of oral  @entity3 in these settings in addition to palliative care services.

title: Where there is no XXXX : The challenge and hope of palliative care delivery in Tanzania.

answer: @entity3


abstract: BACKGROUND: In vitro @entity2 in feline blood samples is a well-known phenomenon in veterinary clinical laboratories resulting in high numbers of pseudothrombocytopenia. Several attempts have been made to prevent or dissolve platelet aggregates in feline blood samples and to increase the @entity2 . @entity4 ( @entity4 ) is the most powerful endogenous inhibitor of @entity2 but unstable. Iloprost is a stable @entity4 analogue. The aims of the present study were (1) to evaluate the anti-aggregatory effect of Iloprost on feline platelet counts and to determine a useful concentration to inhibit @entity2 in @entity1 samples from clinically healthy @entity0 , (2) to investigate the effect of @entity3 , and (3) to determine stability of Iloprost in K3- @entity1 tubes for up to 16 weeks. From 20 clinically healthy @entity0 blood was drawn from the jugular vein and immediately distributed in a 1.3 ml K3- @entity1 tube, and two 1.3 ml K3- @entity1 tubes containing 20 ng and 200 ng Iloprost, respectively. A complete blood cell count was performed on the Sysmex XT-2000iV and the Mythic 18 on eight consecutive time points after collection. Blood smears were evaluated for the presence of PLT aggregates. RESULTS: In the absence of Iloprost, pseudothrombocytopenia was observed in 50% of the investigated samples that led to significantly decreased optical PLT counts by a mean of 105 x10(3)/ l, which could be prevented by the addition of 1  L (20 ng) Iloprost leading to an increase in PLT counts by a mean of 108 x10(3)/ l. CONCLUSION: This is the first study showing an anti-aggregatory effect of the @entity4 -analogue Iloprost in feline @entity1 blood. In all clinically healthy @entity0 investigated, pseudothrombocytopenia was prevented by adding Iloprost to @entity1 tubes prior to blood collection. Furthermore, Iloprost was very useful in preventing falsely increased WBC counts in samples with platelet aggregates analyzed on impedance-based hematological instruments. Iloprost is preferable to @entity4 or @entity5 due to its stability and easy and safe handling properties. Cytological evaluations of blood smears as well as other hematological parameters were not influenced to a clinically significant degree by the presence of Iloprost.

title: Effective prevention of pseudothrombocytopenia in feline blood samples with the XXXX analogue Iloprost.

answer: @entity4


abstract: UNASSIGNED: Large platelets with high haemostatic activity may lead to increased @entity3 .. Mean platelet volume ( @entity4 ), an indicator of platelet reactivity, may emerge as a prognostic marker in @entity0 with @entity2 ( @entity2 ). It was the objective of this study to conduct a systematic review and meta-analysis to assess prognostic effects of @entity4 on @entity1 ( @entity1 ) in @entity2 @entity0 . We searched MEDLINE and SCOPUS from inception to January 2, 2014. All studies that reported @entity4 and the incidence of @entity1 in @entity2 @entity0 were included. Two reviewers independently extracted the data. A random-effects model was applied for pooling the mean difference of @entity4 between @entity0 with vs without @entity1 . Among 30 eligible studies, eight studies reported mean difference of @entity4 between @entity1 groups, 11 studies reported @entity4 dichotomous into high vs low @entity4 groups, and 11 studies reported both. The pooled mean difference was 0.69 fL (95   %CI = 0.36, 1.01), i.   e. @entity0 with @entity1 had a @entity4 about 0.69 fL higher than non- @entity1 . @entity0 with higher @entity4 were about 12   % more likely to die than @entity0 with lower @entity4 (RR 1.12; 95   %CI = 1.02-1.24). However, pooling these effects was based on high heterogeneity and the source of heterogeneity could not be identified. This might be explained by many differences among included studies (e.   g. study population, outcomes of interest, analysate, time between blood collection and @entity4 analysis, etc). These findings suggest that @entity4 may be a useful prognostic marker in @entity0 with @entity2 .

title: Prognostic effect of mean platelet volume in @entity0 with XXXX . A systematic review and meta-analysis.

answer: @entity2


abstract: UNASSIGNED: Large platelets with high haemostatic activity may lead to increased @entity3 .. Mean platelet volume ( @entity4 ), an indicator of platelet reactivity, may emerge as a prognostic marker in @entity0 with @entity2 ( @entity2 ). It was the objective of this study to conduct a systematic review and meta-analysis to assess prognostic effects of @entity4 on @entity1 ( @entity1 ) in @entity2 @entity0 . We searched MEDLINE and SCOPUS from inception to January 2, 2014. All studies that reported @entity4 and the incidence of @entity1 in @entity2 @entity0 were included. Two reviewers independently extracted the data. A random-effects model was applied for pooling the mean difference of @entity4 between @entity0 with vs without @entity1 . Among 30 eligible studies, eight studies reported mean difference of @entity4 between @entity1 groups, 11 studies reported @entity4 dichotomous into high vs low @entity4 groups, and 11 studies reported both. The pooled mean difference was 0.69 fL (95   %CI = 0.36, 1.01), i.   e. @entity0 with @entity1 had a @entity4 about 0.69 fL higher than non- @entity1 . @entity0 with higher @entity4 were about 12   % more likely to die than @entity0 with lower @entity4 (RR 1.12; 95   %CI = 1.02-1.24). However, pooling these effects was based on high heterogeneity and the source of heterogeneity could not be identified. This might be explained by many differences among included studies (e.   g. study population, outcomes of interest, analysate, time between blood collection and @entity4 analysis, etc). These findings suggest that @entity4 may be a useful prognostic marker in @entity0 with @entity2 .

title: Prognostic effect of mean platelet volume in XXXX with @entity2 . A systematic review and meta-analysis.

answer: @entity0


abstract: BACKGROUND: Statins have been shown to be beneficial in primary and secondary prevention settings; however, their role in the elderly remains a clinical conundrum, given that age-related factors could alter the risk-benefit ratio of statin treatment. This study aimed to critically evaluate the efficacy and safety of statins for primary prevention of @entity3 ( @entity3 ) in the elderly. METHODS: We systematically reviewed randomized controlled trials comparing any statins with placebo or usual care for primary prevention of @entity3 in subjects aged >= 65 years. Relative risks (RRs) using a random effects model were calculated and sensitivity analyses were performed to assess the robustness of findings. RESULTS: Eight studies (n = 25,952) were included in the meta-analysis. Statins significantly reduced the risks of composite major adverse cardiovascular events (RR 0.82, 95% CI 0.74-0.92), nonfatal @entity6 [ @entity6 ] (0.75, 0.59-0.94) and total @entity6 (0.74, 0.61-0.90). Treatment effects of statins were statistically insignificant in fatal @entity6 (0.43, 0.09-2.01), @entity2 (fatal: 0.76, 0.24-2.45; nonfatal: 0.76, 0.53-1.11; total: 0.85, 0.68-1.06) and all-cause mortality (0.96, 0.88-1.04). Significant differences were not observed in @entity7 (0.88, 0.69-1.13), elevation of hepatic transaminases (0.98, 0.71-1.34), new-onset @entity1 (1.07, 0.77-1.48), serious adverse events (1.00, 0.97-1.04) and discontinuation due to adverse events (1.10, 0.85-1.42). The occurrence of @entity5 , @entity8 and @entity4 was largely unreported in the included trials. CONCLUSIONS: From a risk-benefit perspective, there is a role of statins for the primary prevention of major adverse cardiovascular events in elderly @entity0 . Further studies are needed to ascertain the benefits of statins on fatal @entity6 , @entity2 and all-cause mortality.

title: Statins for Primary Prevention of XXXX in Elderly @entity0 : Systematic Review and Meta-Analysis.

answer: @entity3


abstract: BACKGROUND: Statins have been shown to be beneficial in primary and secondary prevention settings; however, their role in the elderly remains a clinical conundrum, given that age-related factors could alter the risk-benefit ratio of statin treatment. This study aimed to critically evaluate the efficacy and safety of statins for primary prevention of @entity3 ( @entity3 ) in the elderly. METHODS: We systematically reviewed randomized controlled trials comparing any statins with placebo or usual care for primary prevention of @entity3 in subjects aged >= 65 years. Relative risks (RRs) using a random effects model were calculated and sensitivity analyses were performed to assess the robustness of findings. RESULTS: Eight studies (n = 25,952) were included in the meta-analysis. Statins significantly reduced the risks of composite major adverse cardiovascular events (RR 0.82, 95% CI 0.74-0.92), nonfatal @entity6 [ @entity6 ] (0.75, 0.59-0.94) and total @entity6 (0.74, 0.61-0.90). Treatment effects of statins were statistically insignificant in fatal @entity6 (0.43, 0.09-2.01), @entity2 (fatal: 0.76, 0.24-2.45; nonfatal: 0.76, 0.53-1.11; total: 0.85, 0.68-1.06) and all-cause mortality (0.96, 0.88-1.04). Significant differences were not observed in @entity7 (0.88, 0.69-1.13), elevation of hepatic transaminases (0.98, 0.71-1.34), new-onset @entity1 (1.07, 0.77-1.48), serious adverse events (1.00, 0.97-1.04) and discontinuation due to adverse events (1.10, 0.85-1.42). The occurrence of @entity5 , @entity8 and @entity4 was largely unreported in the included trials. CONCLUSIONS: From a risk-benefit perspective, there is a role of statins for the primary prevention of major adverse cardiovascular events in elderly @entity0 . Further studies are needed to ascertain the benefits of statins on fatal @entity6 , @entity2 and all-cause mortality.

title: Statins for Primary Prevention of @entity3 in Elderly XXXX : Systematic Review and Meta-Analysis.

answer: @entity0


abstract: INTRODUCTION: To describe the technique of total extraperitoneal @entity1 repair performed during Robot-assisted Endoscopic Extraperitoneal Radical Prostatectomy (R-EERPE) and to present the initial outcomes. MATERIAL AND METHODS: 12 @entity0 underwent @entity1 repair during 120 R-EERPEs performed between July 2011 and March 2012. All @entity0 had a clinically palpable @entity1 preoperatively. The @entity3 was repaired using a Total Extraperitoneal Patch (TEP) at the end of the procedure. RESULTS: Sac dissection and mesh placement was simpler compared to conventional laparoscopy due to improved, magnified, 3-D vision along with 7   of movement, and better control of mesh placement. The median operating time was 185 minutes, with on average, an additional 12 minutes incurred per @entity3 repair. The median @entity2 for the procedures was 250 ml, and the mean pathological prostate weight was 55 gm. No additional @entity2 was noted and there were no postoperative complications. None of the @entity0 had a recurrence at 12 months. We await long-term follow-up data. CONCLUSIONS: Robot-assisted TEP is feasible and should be considered in @entity0 with @entity3 at the time of R-EERPE.

title: Robot-assisted laparoscopic total extraperitoneal XXXX repair during prostatectomy: technique and initial experience.

answer: @entity3


abstract: Dural @entity1 from @entity4 is rare and may mimic a @entity7 ( @entity7 ). Preoperatively diagnosis may be difficult and only reveal its presence during surgery. We present such a case and review the literature to identify common characteristics. A 65-year-old @entity0 presented with @entity3 , @entity6 , and progressive @entity5 . Past history included a @entity4 with bone @entity1 3 years earlier. Head computed tomography (CT) scan without contrast revealed a multinodular bilateral hyperdense extra-axial lesion interpreted as acute @entity7 . At surgery planned for @entity7 drainage no blood was found; instead there was an en plaque subdural @entity2 . Histopathologic examination was consistent with metastatic @entity4 . We found 11 cases reported as dural @entity1 of @entity4 mimicking @entity7 . Surgery was performed on nine cases with no suspicion of dural @entity1 . On preoperative nonenhanced CT scan images, three types of image patterns can be described: a nodule in @entity7 , multinodular @entity1 surrounded by @entity7 , and large en plaque subdural @entity2 . The latter group consists of those cases where no blood but rather an en plaque subdural @entity2 was found at surgery. Even though rare, dural @entity1 should be considered among the differential diagnoses in a @entity0 known for @entity4 .

title: Subdural @entity1 of XXXX .

answer: @entity4


abstract: Dural @entity1 from @entity4 is rare and may mimic a @entity7 ( @entity7 ). Preoperatively diagnosis may be difficult and only reveal its presence during surgery. We present such a case and review the literature to identify common characteristics. A 65-year-old @entity0 presented with @entity3 , @entity6 , and progressive @entity5 . Past history included a @entity4 with bone @entity1 3 years earlier. Head computed tomography (CT) scan without contrast revealed a multinodular bilateral hyperdense extra-axial lesion interpreted as acute @entity7 . At surgery planned for @entity7 drainage no blood was found; instead there was an en plaque subdural @entity2 . Histopathologic examination was consistent with metastatic @entity4 . We found 11 cases reported as dural @entity1 of @entity4 mimicking @entity7 . Surgery was performed on nine cases with no suspicion of dural @entity1 . On preoperative nonenhanced CT scan images, three types of image patterns can be described: a nodule in @entity7 , multinodular @entity1 surrounded by @entity7 , and large en plaque subdural @entity2 . The latter group consists of those cases where no blood but rather an en plaque subdural @entity2 was found at surgery. Even though rare, dural @entity1 should be considered among the differential diagnoses in a @entity0 known for @entity4 .

title: Subdural XXXX of @entity4 .

answer: @entity1


abstract: UNASSIGNED: This study aims to evaluate the long-term outcome of major @entity4 ( @entity4 ). This is a retrospective review of 54 cases of @entity4 during a 35-year period from 1974 to 2009 at the Helsinki University Central Hospital, Helsinki, Finland. Medical records and histological samples were reviewed. All @entity0 had a minimum follow-up time of 5  years or until @entity3 . Most of the @entity1 occurred in the parotid gland (n   =   30, 56  %) followed by submandibular gland (n   =   22, 41  %) and sublingual gland (n   =   2, 4  %). Fifty-two @entity0 (96  %) were treated with curative intent. All of these @entity0 except one were primarily treated with surgery, and 29 @entity0 (54  %) also received postoperative radiotherapy for their primary @entity1 . Two @entity0 (4  %) received palliative radiotherapy. For those treated with curative intent, 32 @entity0 (62  %) had disease recurrence. Twenty-four @entity0 (75  %) had their first disease recurrence within 5  years and eight @entity0 (25  %) later than 5  years. The difference in the length of recurrence-free time interval (<5 vs. >5  years) had a significant impact on 5-year overall survival (OS) and @entity2 ( @entity2 ). The OS, @entity2 and disease-free survival (DFS) across stages I-IV varied between 46-100, 50-100 and 46-100  %, respectively. Age over 45  years, T stage, and presence of neck metastases had a significant negative prognostic effect. More than half of the @entity0 had recurrent disease. An extended follow-up for these @entity0 seems feasible as most of the distant metastases were detected within a 10-year period.

title: Pattern of recurrent disease in major XXXX .

answer: @entity4


abstract: Clinical effects of @entity1 ( @entity7 ) in the treatment of @entity5 was compared with those in the treatment of @entity5 . @entity6 was isolated from 33 (39.3%) out of 84 @entity0 with @entity4 . @entity7 was administered at a dose of 100 mg, three times daily (300 mg) for 14 days. In 31 (93.3%) of the 33 @entity0 with @entity5 , @entity6 was eliminated within 7 to 14 days after the start of administration, and, in two @entity0 , inclusion bodies decreased in number but persisted. The subjective and objective clinical symptoms, urethral discharge, polymorphonuclear leucocyte (PMNL) in smears, and @entity2 in VB1 of the @entity0 with @entity5 , disappeared in 56.0, 57.6, and 63.0% of the cases, and improved in 24.0, 30.0 and 29.6% respectively, whereas those of the @entity0 with @entity5 , urethral discharge, PMNL, and @entity2 in VB1 disappeared in 57.6, 56.9 and 32.9%, and improved in 26.9, 13.7 and 37.9%, respectively. There was no significant difference in the clinical effects of @entity7 between cases of @entity5 and those of @entity5 . Marked improvement in clinical symptoms were observed between day 7 and day 14 of medication in cases of both chlamydial and @entity5 . In nine out of 11 cases of @entity5 where @entity7 was ineffective, no Ureaplasma nor aerobes, nor @entity6 , were isolated. In the remaining two cases where Ureaplasma and @entity3 were isolated respectively, these two bacteria were eradicated after medication, but urethral discharge and PMNL remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Treatment of XXXX --studies on clinical effects of @entity1 ].

answer: @entity4


abstract: Clinical effects of @entity1 ( @entity7 ) in the treatment of @entity5 was compared with those in the treatment of @entity5 . @entity6 was isolated from 33 (39.3%) out of 84 @entity0 with @entity4 . @entity7 was administered at a dose of 100 mg, three times daily (300 mg) for 14 days. In 31 (93.3%) of the 33 @entity0 with @entity5 , @entity6 was eliminated within 7 to 14 days after the start of administration, and, in two @entity0 , inclusion bodies decreased in number but persisted. The subjective and objective clinical symptoms, urethral discharge, polymorphonuclear leucocyte (PMNL) in smears, and @entity2 in VB1 of the @entity0 with @entity5 , disappeared in 56.0, 57.6, and 63.0% of the cases, and improved in 24.0, 30.0 and 29.6% respectively, whereas those of the @entity0 with @entity5 , urethral discharge, PMNL, and @entity2 in VB1 disappeared in 57.6, 56.9 and 32.9%, and improved in 26.9, 13.7 and 37.9%, respectively. There was no significant difference in the clinical effects of @entity7 between cases of @entity5 and those of @entity5 . Marked improvement in clinical symptoms were observed between day 7 and day 14 of medication in cases of both chlamydial and @entity5 . In nine out of 11 cases of @entity5 where @entity7 was ineffective, no Ureaplasma nor aerobes, nor @entity6 , were isolated. In the remaining two cases where Ureaplasma and @entity3 were isolated respectively, these two bacteria were eradicated after medication, but urethral discharge and PMNL remained unchanged.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Treatment of @entity4 --studies on clinical effects of XXXX ].

answer: @entity1


abstract: OBJECTIVE: Quantitative electroencephalography (qEEG) has been increasingly used to evaluate @entity0 with @entity1 ( @entity1 ). The aim of this study was to assess the correlation between qEEG data and symptom severity in @entity0 with @entity1 . METHODS: Fifteen @entity0 with @entity1 and 20 healthy controls (HCs) were recruited. Electroencephalography was assessed in the resting-state, and qEEG data were obtained in the eyes-closed state. The Korean version of the @entity1 Rating Scale (K-ARS) and continuous performance tests (CPTs) were used to assess all @entity0 . RESULTS: Theta-band (4-7 Hz) power across the brain was significantly positively correlated with inattention scores on the K-ARS, reaction times and commission errors on the CPTs in @entity1 @entity0 . Gamma-band (31-50 Hz) power was significantly positively correlated with the results of the auditory CPTs in @entity1 @entity0 . The theta/alpha (8-12 Hz) and theta/beta (13-30 Hz) ratios were significantly negatively correlated with commission and omission errors on auditory CPTs in @entity1 @entity0 . No significant correlations between qEEG relative power and K-ARS and CPT scores were observed in HCs. CONCLUSION: Our results suggest that qEEG may be a useful adjunctive tool in @entity0 with @entity1 .

title: Quantitative Electroencephalography Reflects Inattention, Visual Error Responses, and Reaction Times in Male XXXX with Attention Deficit Hyperactivity Disorder.

answer: @entity0


abstract: Due to the evidence for two distinct steroidogenic cell types in corpora lutea of large domestic animals, cells of the @entity0 corpus luteum were characterized with respect to cell diameters, relative abundance, steroidogenic capacity and responsiveness to hormones. Pseudopregnancy was induced in @entity0 by injection of 30-160 IU pregnant mare's serum gonadotropin (PMSG) followed in 2-4 days by an i.m. injection of 20-35 micrograms @entity1 ( @entity1 ). Corpora lutea were obtained 2, 5 and 9 days after injection of @entity1 and dissociated into single cell suspensions. Suspended steroidogenic cells were incubated (2 h, 37 degrees C) in medium 199 alone or in medium containing ovine luteinizing hormone (oLH) (100 ng/ml), or @entity4 (100 microM). Media were collected and assayed for @entity2 content. Secretion of @entity2 (means +/- SE, n = 4) was stimulated (p less than 0.05) by oLH on each day: Day 2 = 1.7 +/- 0.2-fold; Day 5 = 3.5 +/- 0.4-fold; and Day 9 = 3.1 +/- 0.6-fold stimulation above controls. @entity4 also stimulated (p less than 0.05) secretion of @entity2 by suspended luteal cells on Days 2 and 9. Microscopic examination of cell suspensions stained for @entity3 dehydrogenase (3 beta HSD) activity provided identification of cells with steroidogenic capacity. The diameters (means +/- SE) for steroidogenic cells increased (p less than 0.05) from Days 2 to 9 (Day 2 = 15.2 +/- 0.2 micron; Day 5 = 22.4 +/- 0.4 micron; Day 9 = 28.3 +/- 1.6 micron). The large cell to small cell ratio increased from 0.01 on Day 2 to 2.03 on Day 9.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Size distribution and hormonal responsiveness of dispersed XXXX luteal cells during pseudopregnancy.

answer: @entity0


abstract: BACKGROUND: Although @entity3 is a preventable disease, it remains the second leading cause of @entity2 (after @entity1 ) among @entity0 aged under five years worldwide. The World Health Organization (WHO) scale, the Gorelick scale, and the Clinical Dehydration Scale (CDS) were created to estimate @entity4 status using clinical signs. The purpose of this study is to determine whether these clinical scales can accurately assess @entity4 status of @entity0 in a developing country of Kosovo. METHODOLOGY: @entity0 aged 1 month to 5 years with a history of acute @entity3 were enrolled in the study. After recording the data about the @entity0 historical features the treating physician recorded the physical examination findings consistent with each clinical score. Receiver operating characteristic (ROC) curves were constructed to evaluate the performance of the three scales, compared to the gold standard, percent weight change with rehydration. Sensitivity, specificity and likelihood ratios were calculated using the best cut-off points of the ROC curves. RESULTS: We enrolled 230 @entity0 , and 200 @entity0 met eligibility criteria. The WHO scale for predicting significant @entity4 (>= 5 percent weight change) had an area under the curve (AUC) of 0.71 (95% : CI= 0.65-0.77). The Gorelick scales 4- and 10-point for predicting significant @entity4 , had an area under the curve of 0.71 (95% : CI=0.63- 0.78) and 0.74 (95% : CI= 0.68-0.81) respectively. Only the CDS for predicting the significant @entity4 above >= 6% percent weight change, did not have an area under the curve statistically different from the reference line with an AUC of 0.54 (95% CI = 0.45- 0.63). CONCLUSION: The WHO @entity4 scale and Gorelick scales were fair predictors of @entity4 in @entity0 with @entity3 . Only the Clinical Dehydration Scale was found not to be a helpful predictor of @entity4 in our study cohort.

title: Comparing the Accuracy of the Three Dehydration Scales in @entity0 with Acute XXXX in a Developing Country of Kosovo.

answer: @entity3


abstract: BACKGROUND: Although @entity3 is a preventable disease, it remains the second leading cause of @entity2 (after @entity1 ) among @entity0 aged under five years worldwide. The World Health Organization (WHO) scale, the Gorelick scale, and the Clinical Dehydration Scale (CDS) were created to estimate @entity4 status using clinical signs. The purpose of this study is to determine whether these clinical scales can accurately assess @entity4 status of @entity0 in a developing country of Kosovo. METHODOLOGY: @entity0 aged 1 month to 5 years with a history of acute @entity3 were enrolled in the study. After recording the data about the @entity0 historical features the treating physician recorded the physical examination findings consistent with each clinical score. Receiver operating characteristic (ROC) curves were constructed to evaluate the performance of the three scales, compared to the gold standard, percent weight change with rehydration. Sensitivity, specificity and likelihood ratios were calculated using the best cut-off points of the ROC curves. RESULTS: We enrolled 230 @entity0 , and 200 @entity0 met eligibility criteria. The WHO scale for predicting significant @entity4 (>= 5 percent weight change) had an area under the curve (AUC) of 0.71 (95% : CI= 0.65-0.77). The Gorelick scales 4- and 10-point for predicting significant @entity4 , had an area under the curve of 0.71 (95% : CI=0.63- 0.78) and 0.74 (95% : CI= 0.68-0.81) respectively. Only the CDS for predicting the significant @entity4 above >= 6% percent weight change, did not have an area under the curve statistically different from the reference line with an AUC of 0.54 (95% CI = 0.45- 0.63). CONCLUSION: The WHO @entity4 scale and Gorelick scales were fair predictors of @entity4 in @entity0 with @entity3 . Only the Clinical Dehydration Scale was found not to be a helpful predictor of @entity4 in our study cohort.

title: Comparing the Accuracy of the Three Dehydration Scales in XXXX with Acute @entity3 in a Developing Country of Kosovo.

answer: @entity0